Thank you.
The plan continues to evolve and it keeps being adapted, etc. We are obviously looking at all options, not just in Canada but internationally. We're working with the WHO, with the Americans and Mexicans and others in terms of effective responses--what the alternatives are, the appropriateness of distancing measures, what other things might actually be effective.
Unfortunately with the antivirals, every antiviral known eventually will have resistance. That's why we, a long time ago, started to diversify with the addition of Relenza, to which none of the influenza viruses we've seen has yet developed resistance. So we've been focusing on adding to—and not replacing Tamiflu completely, but a lot of that being Relenza. Right now there are no other licensed products available, but there is research on a number of other options going forward.
There is a number that are expiring. Some are expiring this year, some next year. We're working with the provinces and territories to replace those.